Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression

被引:19
作者
Coulibaly, Bema [1 ,2 ]
Nanni, Isabelle [3 ]
Quilichini, Benoit [2 ]
Gaudart, Jean [4 ]
Metellus, Philippe [5 ]
Fina, Frederic [3 ]
Boucard, Celine [6 ]
Chinot, Olivier [6 ]
Ouafik, L'Houcine [2 ]
Figarella-Branger, Dominique [1 ,2 ]
机构
[1] CHU Timone, Dept Anat Pathol & Neuropathol, F-13005 Marseille, France
[2] Fac Med Timone, INSERM, UMR 911, Lab Angiogenese Invas & Microenvironm Tumoral, F-13385 Marseille 05, France
[3] Fac Med Nord, Lab Transfer Oncol Biol, F-13016 Marseille, France
[4] CHU Timone, Unite Fonct Biostat & Methodol Rech Clin, SSPIM, LERTIM, F-13005 Marseille, France
[5] CHU Timone, Dept Neurochirurg, F-13005 Marseille, France
[6] CHU Timone, Dept Neurooncol, F-13005 Marseille, France
关键词
Glioblastoma; Epidermal growth factor receptor; Immunohistochemistry; Gene amplification; Fluorescence in situ hybridization; PHASE-II; AMPLIFICATION; MULTIFORME; INHIBITION; GEFITINIB; MUTATION; GLIOMA; IMPACT; AGE;
D O I
10.1016/j.humpath.2009.09.020
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
Epidermal growth factor receptor is a transmembrane receptor involved in oncogenesis, including the development of glioblastoma. We studied the prognostic significance of epidermal growth factor receptor amplification as determined by fluorescence in situ hybridization, quantitative polymerase chain reaction, and protein expression by immunohistochemistry. Ninety-nine patients exhibiting glioblastoma were included. Immunohistochemistry was performed on microarray blocks with clone 25, which recognizes both epidermal growth factor receptor wild type and VIII, and scored using a semiquantitative approach. Quantitative polymerase chain reaction and fluorescence in situ hybridization techniques were performed on frozen section: 29.3% of cases had a high epidermal growth factor receptor immunohistochemistry score (score >= 200); and of these cases, 96.5% had gene amplification by fluorescence in situ hybridization and quantitative polymerase chain reaction. Conversely, of cases with a low immunohistochemistry score, 72.9% had normal karyotype or polysomy 7 by fluorescence in situ hybridization technique; but around 25% had gene amplification by fluorescence in situ hybridization and quantitative polymerase chain reaction. In the case of protein overexpression, quantitative polymerase chain reaction and fluorescence in situ hybridization could be avoided in first intention because their positive predictive value for amplification is 97%. In multivariate analysis, there was a trend toward an association between shorter overall survival time and epidermal growth factor receptor amplification as determined by fluorescence in situ hybridization analysis. However, cases with an immunohistochemistry score less 200 require further testing by fluorescence in situ hybridization or quantitative polymerase chain reaction. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:815 / 823
页数:9
相关论文
共 21 条
[1]
Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro [J].
Andersson, Ulrika ;
Johansson, David ;
Behnam-Motlagh, Parviz ;
Johansson, Mikael ;
Malmer, Beatrice .
ACTA ONCOLOGICA, 2007, 46 (07) :951-960
[2]
Age-dependent prognostic effects of genetic alterations in glioblastoma [J].
Batchelor, TT ;
Betensky, RA ;
Esposito, JM ;
Pham, LDD ;
Dorfman, MV ;
Piscatelli, N ;
Jhung, S ;
Rhee, D ;
Louis, DN .
CLINICAL CANCER RESEARCH, 2004, 10 (01) :228-233
[3]
In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab [J].
Combs, Stephanie E. ;
Schulz-Ertner, Daniela ;
Roth, Wilfried ;
Herold-Mende, Christel ;
Debus, Juergen ;
Weber, Klaus-Josef .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (03) :873-882
[4]
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma [J].
de Groot, J. F. ;
Gilbert, M. R. ;
Aldape, K. ;
Hess, K. R. ;
Hanna, T. A. ;
Ictech, S. ;
Groves, M. D. ;
Conrad, C. ;
Colman, H. ;
Puduvalli, V. K. ;
Levin, V. ;
Yung, W. K. A. .
JOURNAL OF NEURO-ONCOLOGY, 2008, 90 (01) :89-97
[5]
Donato V, 2007, TUMORI, V93, P248
[6]
AMPLIFIED AND REARRANGED EPIDERMAL GROWTH-FACTOR RECEPTOR GENES IN HUMAN GLIOBLASTOMAS REVEAL DELETIONS OF SEQUENCES ENCODING PORTIONS OF THE N-TERMINAL AND OR C-TERMINAL TAILS [J].
EKSTRAND, AJ ;
SUGAWA, N ;
JAMES, CD ;
COLLINS, VP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4309-4313
[7]
Gefitinib in patients with progressive high-grade gliomas:: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) [J].
Franceschi, E. ;
Cavallo, G. ;
Lonardi, S. ;
Magrini, E. ;
Tosoni, A. ;
Grosso, D. ;
Scopece, L. ;
Blatt, V. ;
Urbini, B. ;
Pession, A. ;
Tallini, G. ;
Crino, L. ;
Brandes, A. A. .
BRITISH JOURNAL OF CANCER, 2007, 96 (07) :1047-1051
[8]
Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis [J].
Hirsch, FR ;
Varella-Garcia, M ;
Bunn, PA ;
Di Maria, MV ;
Veve, R ;
Bremnes, RM ;
Barón, AE ;
Zeng, C ;
Franklin, WA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) :3798-3807
[9]
Prognostic impact of molecular markers in a series of 220 primary glioblastomas [J].
Houillier, C ;
Lejeune, J ;
Benouaich-Amiel, A ;
Laigle-Donadey, F ;
Criniere, E ;
Mokhtari, K ;
Thillet, J ;
Delaffre, JY ;
Hoang-Xuan, K ;
Sanson, M .
CANCER, 2006, 106 (10) :2218-2223
[10]
Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: Results of a meta-analysis [J].
Huncharek, M ;
Kupelnick, B .
ONCOLOGY RESEARCH, 2000, 12 (02) :107-112